H. pylori antibiotic-resistance markers: what they can tell you

Published October 7, 2026 · Updated November 18, 2026 · 5 min read

The H. pylori antibiotic-resistance section of a GI-MAP test looks for selected genetic changes linked to resistance. A positive finding can help a prescriber assess treatment options. A negative finding is not a guarantee that treatment will work, and “N/A” is not a negative resistance result. Start by checking which section and result column you are reading.

On this page

What the GI-MAP resistance section covers

The laboratory’s public sample lists H. pylori resistance targets for clarithromycin, amoxicillin, fluoroquinolones and tetracycline. Check the names on your own report; this is a selected genetic panel, not testing of every possible antibiotic. [2]

Why does my report say N/A?

The manufacturer’s 2025 guide says H. pylori resistance results are reported only when the H. pylori quantity is 5.0e2 or greater—500 in scientific notation. That reporting threshold is different from the organism’s reference limit and is not, by itself, a treatment threshold. Ask the ordering clinician or laboratory about a missing or unexpected result. [1]

Worked example: the laboratory’s public demonstration report shows H. pylori below the detectable limit on page 2. Its resistance rows on page 5 say N/A, while the adjacent reference column says Negative. The reference is a comparison label, not the reported result. That example does not establish antibiotic susceptibility. It is a demonstration report, not your personal result. The GI-MAP sample-report walkthrough explains how to keep result and reference columns separate. [2]

Detected does not mean untreatable

For clarithromycin, labels such as A2142C, A2142G and A2143G name specific genetic variants. These are also the three common variants targeted by Mayo Clinic Laboratories’ separate stool PCR test. Genetic prediction asks a different question from growing an organism and measuring its susceptibility to a drug. Mayo’s test documentation is useful context, but its performance figures cannot be transferred to GI-MAP. [4]

A detected variant does not mean every treatment will fail. The American College of Gastroenterology’s 2024 guidance advises against clarithromycin- or levofloxacin-containing regimens unless susceptibility is demonstrated. Choosing a regimen requires a prescriber to consider prior treatment and the complete clinical picture. Do not start, stop or replace a prescribed medicine from this table alone. [3]

Not detected does not guarantee success

A molecular result addresses the variants included in that assay. Other resistance mechanisms may be outside its scope. For example, Mayo’s clarithromycin PCR documentation expressly excludes other resistance mechanisms and resistance to other drugs. Its caution illustrates why “not detected” should not be expanded into “all antibiotics will work.” Each assay needs its own interpretation and validation. [4]

Before the appointment, gather the original report and a simple treatment history:

  • Names and dates of previous H. pylori regimens and other antibiotics.
  • Any missed doses, vomiting, side effects or difficulty finishing treatment.
  • Recorded medication allergies and what happened when the medicine was taken.
  • The result and timing of any previous test of cure.

This is a discussion checklist, not a scoring system. A report cannot supply the history or choose the next prescription.

Resistance and virulence are different

cagA and vacA belong to the virulence section; they are not substitutes for resistance variants. Keep these questions separate: was H. pylori detected, which virulence targets were reported, and was the resistance section reportable? The H. pylori result guide covers the organism finding. [1]

Common questions

Is the universal resistance panel the same as the H. pylori section?

No. The optional universal panel is separate. Its report warns that detected genes cannot be assigned to particular microbes and may not correspond to expressed drug resistance. Do not attach a universal-panel flag to H. pylori or another named bacterium yourself. [2]

Can I choose treatment from the resistance table myself?

No. Take the finding to the prescriber, including the exact variant and report date. Ask whether the available result adequately answers the treatment question or whether different testing is needed. A list of resistance markers is not a prescription.

Do I still need a test of cure?

Yes. ACG recommends confirming eradication after treatment with a urea breath test, fecal antigen test or biopsy-based test. Plan it at least four weeks after therapy. The guideline advises appropriate pauses in PPIs, antibiotics and bismuth to avoid false negatives; agree on timing and medication instructions with the clinician. A resistance row is not proof of eradication. [3]

Sources and review

Sources checked November 18, 2026. Manufacturer documents establish report layout and assay scope; clinical guidance informs treatment and follow-up context. No medical review or treatment plan is implied.

  1. Diagnostic Solutions Laboratory: GI-MAP interpretive guide, 2025 edition
  2. Diagnostic Solutions Laboratory: public sample report, pages 2, 5 and 6
  3. American College of Gastroenterology: H. pylori guideline highlights, 2024
  4. Mayo Clinic Laboratories: stool PCR with clarithromycin resistance prediction, interpretation and cautions

This article has been reviewed by Madison Ordway, FDN-P. For a correction or source question, contact Gi Map Test.